Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Fresh from the Pipeline
  • Published:

Sipuleucel-T

Abstract

In April 2010, sipuleucel-T (Provenge; Dendreon), an autologous cellular immunotherapy, was approved by the US FDA for the treatment of asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. It is the first therapeutic cancer vaccine to receive FDA approval.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Jemal, A. Cancer statistics, 2009. CA Cancer J. Clin. 59, 225–249 (2009).

    Article  Google Scholar 

  2. Oh, W. K. & Schurko, B. Docetaxel chemotherapy remains the standard of care in castration-resistant prostate cancer. Nature Clin. Pract. Oncol. 5, 506–507 (2008).

    Article  Google Scholar 

  3. Patel, P. H. & Kockler, D. R. Sipuleucel-T: a vaccine for metastatic, asymptomatic, androgen-independent prostate cancer. Ann. Pharmacother. 42, 91–98 (2008).

    Article  Google Scholar 

  4. Gilboa, E. The promise of cancer vaccines. Nature Rev. Cancer 4, 401–411 (2004).

    Article  CAS  Google Scholar 

  5. US Food and Drug Administration. FDA labelling information — Provenge. FDA website [online], (2010).

  6. Small, E. J. et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J. Clin. Oncol. 18, 3894–3903 (2000).

    Article  CAS  Google Scholar 

  7. Burch, P. A. et al. Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer. Clin. Cancer Res. 6, 2175–2182 (2000).

    CAS  PubMed  Google Scholar 

  8. Small, E. J. et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J. Clin. Oncol. 24, 3089–3094 (2006).

    Article  CAS  Google Scholar 

  9. Tannock, I. F. et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 351, 1502–1512 (2004).

    Article  CAS  Google Scholar 

  10. Petrylak, D. P. et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med. 351, 1488–1490 (2004).

    Article  Google Scholar 

  11. Beer, T. M. et al. Randomized trial of active cellular immunotherapy with sipuleucel-T in androgen dependent prostate cancer (ADPC). J. Clin. Oncol. 25, 18S (2007).

    Article  Google Scholar 

  12. Kelly, W. et al. A randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): Survival results of CALGB 90401. J. Clin. Oncol. 28, 344s (2010).

    Google Scholar 

  13. IMS MIDAS (2009).

  14. Reams, A. & Andrews, M. J. Biotechnology equity research report. Wells Fargo Securities (19 May 2010).

  15. Kasimov, C., Ashiya M. & Jay, K. Equity research report. JP Morgan North America (11 May 2010).

Download references

Author information

Authors and Affiliations

Authors

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Higano, C., Small, E., Schellhammer, P. et al. Sipuleucel-T. Nat Rev Drug Discov 9, 513–514 (2010). https://doi.org/10.1038/nrd3220

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd3220

This article is cited by

Search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research